Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:32 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 1,548 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ulcers Clear all
Completed No phase listed Observational

Partial Wave Spectroscopic Detection of Colon Cancer Risk

NCT01095432
View directory record Official record
Conditions
Ulcerative Colitis, Colon Cancer
Interventions
PWS Testing
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 23, 2016 · Synced Oct 27, 2026, 4:32 AM EDT
Recruiting Not applicable Interventional

Clinical Trial Evaluating an Amnion Membrane Allograft for Use in the Management of Non- Healing Diabetic Foot Ulcers Versus Standard Of Care

NCT06767501
View directory record Official record
Conditions
Diabetic Foot Ulcers (DFUs)
Interventions
E-GRAFT ™, FIBRACOL™
Other · Device
Lead sponsor
Skye Biologics Holdings, LLC
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Upper GI Ulceration Induced by PL2200 Versus Aspirin in At-Risk Subjects

NCT01646814
View directory record Official record
Conditions
Gastroduodenal Ulceration
Interventions
PL2200, Aspirin tablets
Drug
Lead sponsor
PLx Pharma
Industry
Eligibility
50 Years to 75 Years
Enrollment
247 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
10
States / cities
Jupiter, Florida • South Miami, Florida • Towson, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 27, 2026, 4:32 AM EDT
Recruiting Not applicable Interventional

Ketogenic and Carnivore (Lion) Diets for Inflammatory Bowel Disease and Rheumatoid Arthritis

NCT07524244
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Crohn's Disease (CD), Ulcerative Colitis (UC)
Interventions
Ketogenic diet, Carnivore (Lion) Diet
Behavioral
Lead sponsor
Fuller Research Foundation
Other
Eligibility
18 Years to 64 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 27, 2026, 4:32 AM EDT
Terminated Phase 4 Interventional Results available

Use of INTEGRA™ Flowable Wound Matrix to Manage Diabetic Foot Ulcers

NCT01108263
View directory record Official record
Conditions
Diabetes, Foot Ulcer
Interventions
INTEGRA™ Flowable Matrix (Collagen)
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Oct 27, 2026, 4:32 AM EDT
Not listed Phase 1 Interventional

Safety of Secretrol® in the Short-term Management of Patients Undergoing Endoscopic Mucosal Resection (EMR)

NCT02210494
View directory record Official record
Conditions
EMR Ulcer
Interventions
Secretrol
Drug
Lead sponsor
Effexus Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Oct 27, 2026, 4:32 AM EDT
Not listed Not applicable Interventional

A Brief Intervention to Improve Adherence in Teens With Inflammatory Bowel Disease

NCT01237847
View directory record Official record
Conditions
Inflammatory Bowel Disease
Interventions
2 Family-based problem solving phone sessions, 4 Family-based problem solving phone intervention sessions, Wait list comparison group
Behavioral
Lead sponsor
Rosalind Franklin University of Medicine and Science
Other
Eligibility
11 Years to 18 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) vs SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute Mild to Moderate Ulcerative Colitis

NCT00503243
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Delayed and extended release mesalazine
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2021 · Synced Oct 27, 2026, 4:32 AM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Quest to Analyze One Thousand Humans Meditating

NCT06583395
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma, Atrial Fibrillation, Cancer Brain, Cancer, Breast, Cancer Colon, Cancer, Lung, Cancer, Ovarian, Cancer Prostate, Cancer Skin, Throat Cancer, Lymphoma, Cancer, Thyroid, Cancer, Other, Cerebral Palsy, Chronic Fatigue Syndrome, Cluster Headache, Chronic Obstructive Pulmonary Disease (COPD), Chronic Kidney Diseases, Crohn Disease, Deafness, Depression, Diabetes, Eczema, Epilepsy, Fibroids, Fibromyalgia, Heart Failure, Hypertension, Hyperthyroidism, Hypothyroidism, Irritable Bowel Syndrome (IBS), Infertility, Lyme Disease, Macular Degeneration, Migraine, Multiple Allergies, Multiple Sclerosis, Osteoarthritis, Osteoporosis, Ovarian Cysts, Parkinson Disease, Phantom Limb Pain, Psoriasis, Post Traumatic Stress Disorder (PTSD), Rheumatoid Arthritis, Sjogrens Disease, Spinal Cord Injury, Spinal Stenosis, Stroke, Tension Headache, Tinnitus, Ulcerative Colitis
Interventions
Advanced multi-component meditation practice
Behavioral
Lead sponsor
Tobias Moeller-Bertram
Industry
Eligibility
21 Years and older
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Palm Desert, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2024 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 1 Interventional

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

NCT02924402
View directory record Official record
Conditions
B-cell Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukemia
Interventions
XmAb13676
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
10
States / cities
La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 27, 2026, 4:32 AM EDT
Terminated Phase 1Phase 2 Interventional

Safety and Efficacy of Gentamicin Topical Gel (AppliGel-G) for Treatment of Mild to Moderately Infected Diabetic Foot Ulcers

NCT02036528
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Gentamicin Topical Gel, Ciprofloxacin, Doxycycline
Drug
Lead sponsor
Royer Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
7
States / cities
Washington D.C., District of Columbia • Miami, Florida • Miami Lakes, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Nasal Calcitonin in the Treatment of Bone Mineral Loss in Children and Adolescents With Inflammatory Bowel Disease

NCT00114803
View directory record Official record
Conditions
Ulcerative Colitis, Crohn's Disease
Interventions
Calcitonin nasal spray (salmon)
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 22 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2007 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis

NCT01959282
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily, JNJ-54781532 75 mg twice daily
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
219 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
15
States / cities
La Jolla, California • Thornton, Colorado • Ann Arbor, Michigan + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 27, 2026, 4:32 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

WOUNDCHEK™ Protease Status Point of Care (POC) Diagnostic Test

NCT01537003
View directory record Official record
Conditions
Venus Leg Ulcers
Interventions
Promogran, Coban 2 layer
Device
Lead sponsor
Systagenix Wound Management
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Eire, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Not applicable Interventional

Non-weight Bearing Exercise for Accelerated Healing of Diabetic Foot Ulcers

NCT05603273
View directory record Official record
Conditions
Type2diabetes, Foot Ulcer
Interventions
non-weight bearing exercise
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 27, 2026, 4:32 AM EDT
Active, not recruiting Not applicable Interventional

Remote Temperature and Visual Monitoring To Help Manage Diabetic Foot Ulcers

NCT06782386
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
OneStep Foot Scanner
Device
Lead sponsor
Bluedrop Medical Limited
Industry
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
North Port, Florida • Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

NCT00713310
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 400 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 27, 2026, 4:32 AM EDT
Not listed Not applicable Interventional

Modified Platform Trial Evaluating PpLHACM and SOC Versus SOC Alone in the Treatment of Nonhealing DFUs

NCT06600724
View directory record Official record
Conditions
Diabetic Foot Ulcer, Diabetic Foot, Foot Ulcer Due to Type 2 Diabetes Mellitus, Foot Ulcer, Diabetic, Foot Ulcer
Interventions
Standard of Care, EPIEFFECT, EPIXPRESS
Other
Lead sponsor
MiMedx Group, Inc.
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Monroeville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Not applicable Interventional Results available

Clinical Effectiveness of the "PICU Up!" Multifaceted Early Mobility Intervention for Critically Ill Children

NCT04989790
View directory record Official record
Conditions
Child, Intensive Care Unit Acquired Weakness, Critical Illness, Hospital Acquired Pressure Ulcer
Interventions
PICU Up!
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
1,470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
11
States / cities
Madera, California • Orlando, Florida • Louisville, Kentucky + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 27, 2026, 4:32 AM EDT
Recruiting Phase 4 Interventional

Efficacy of Placental Membrane Dressings in Accelerating Diabetic Foot Healing

NCT07326553
View directory record Official record
Conditions
Diabete Mellitus, Foot Ulcer Chronic
Interventions
Placental Membrane
Biological
Lead sponsor
BioXTek
Industry
Eligibility
45 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
2
States / cities
Phoenix, Arizona • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 27, 2026, 4:32 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Ozanimod
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
2 Years to 17 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2032
U.S. locations
36
States / cities
Phoenix, Arizona • Tucson, Arizona • Garden Grove, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 2 Interventional

Study Evaluating Efficacy and Safety of Amiselimod (MT-1303) in Mild to Moderate Ulcerative Colitis

NCT04857112
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose MT-1303, High Dose MT-1303, Placebo, MT-1303
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
22
States / cities
Chandler, Arizona • Los Angeles, California • Rancho Cucamonga, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 27, 2026, 4:32 AM EDT
Terminated Phase 1 Interventional

Effect of an Oral Supplement Enriched in Amino Acids and the Leucine Metabolite B-hydroxy B-methylbutyrate (HMB)

NCT00502372
View directory record Official record
Conditions
Pressure Ulcers
Interventions
Nutritional Supplement/Amino acids and HMB, Juven
Dietary Supplement
Lead sponsor
Central Arkansas Veterans Healthcare System
Federal
Eligibility
21 Years to 90 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2015 · Synced Oct 27, 2026, 4:32 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

NCT00488631
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Placebo, Golimumab 50 mg, Golimumab 100 mg, Golimumab 200 mg
Biological
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
96
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2016 · Synced Oct 27, 2026, 4:32 AM EDT